TGF-beta Antibody (1D11.16.8) - Azide and BSA Free

Immunohistochemistry: TGF-beta Antibody (1D11.16.8) - Azide and BSA Free [NBP2-47736]

Immunohistochemistry: TGF-beta Antibody (1D11.16.8) - Azide and BSA Free [NBP2-47736] - TGF-beta was detected in immersion fixed paraffin-embedded human skin using 25 ug/mL Mouse Anti-TGF-beta Monoclonal Antibody (Clone 1D11.16.8) overnight at 4 degrees C. Tissues was stained using the Anti-Mouse HRP-DAB Cell and Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with Haematoxylin (blue).

Flow Cytometry: TGF-beta Antibody (1D11.16.8) - Azide and BSA Free [NBP2-47736] -

Lymphosuppression of OMC-derived secretome is partially mediated through TGF beta, L-arginine, and induction of nitric oxide synthase (NOS) in lymphocytes. (A). Upper panels, low-magnification (2×) images of mouse lymph nodes (LN) lymphocytes cultured for 48 h in fresh media or OMC-derived secretome (OMC-S), with or without 25 ug/mL phytohemagglutinin (PHA). Scale bar: 500 um. Lower panel, images of mouse LN lymphocytes cultured in the presence of OMC-S + PHA supplemented with 50 uM SB-431542 (selective inhibitor of ALK5/TGF-beta 1 Receptor), 1 ug/mL of a mouse monoclonal anti-TGF- beta1, beta2, and beta3 antibody, 1 mM L-arginine, or 100 uM L-NMMA (specific inhibitor of nitric oxide synthase). (B) Quantification of lymphocyte agglutination in response to the various experimental culture conditions by measuring mean particle size surface (um2). Results shown are mean +/- s.e.m from (n = 3) distinct batches of OMC-S from ALIC1, SEV3, and SEV4. Statistical differences between experimental conditions were calculated using one way ANOVA. * is for p ≤ 0.05; ** for p ≤ 0.01; *** p ≤ 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35682603), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Flow Cytometry: TGF-beta Antibody (1D11.16.8) - Azide and BSA Free [NBP2-47736] -

Lymphosuppression of OMC-derived secretome is partially mediated through TGF beta, L-arginine, and induction of nitric oxide synthase (NOS) in lymphocytes. (A). Upper panels, low-magnification (2×) images of mouse lymph nodes (LN) lymphocytes cultured for 48 h in fresh media or OMC-derived secretome (OMC-S), with or without 25 ug/mL phytohemagglutinin (PHA). Scale bar: 500 um. Lower panel, images of mouse LN lymphocytes cultured in the presence of OMC-S + PHA supplemented with 50 uM SB-431542 (selective inhibitor of ALK5/TGF-beta 1 Receptor), 1 ug/mL of a mouse monoclonal anti-TGF- beta1, beta2, and beta3 antibody, 1 mM L-arginine, or 100 uM L-NMMA (specific inhibitor of nitric oxide synthase). (B) Quantification of lymphocyte agglutination in response to the various experimental culture conditions by measuring mean particle size surface (um2). Results shown are mean +/- s.e.m from (n = 3) distinct batches of OMC-S from ALIC1, SEV3, and SEV4. Statistical differences between experimental conditions were calculated using one way ANOVA. * is for p ≤ 0.05; ** for p ≤ 0.01; *** p ≤ 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35682603), licensed under a CC-BY license. Not internally tested by Novus Biologicals.